Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Feb 12, 2018Phase 1 data is expected in mid-2018Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that the single dose...
- Jan 24, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new...
- Jan 22, 2018Screening of subjects for this first-in-human study has begun and represents an important milestone in advancing this first in class therapy to the clinic
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it has received...
Nov 9, 2017Completed Out-License Agreement for PUR0200 US Rights and Received Award to Advance Development of PulmazolePulmatrix, Inc. (NASDAQ: PULM) today reports its third quarter financial results and provided an overview of recent operational highlights. "During the third quarter, we made significant progress...
Oct 31, 2017Preclinical data show that Pulmatrix's inhaled antifungal drug can achieve high concentrations in the lungs, with low levels in the bloodstreamPulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it will present...
